The Prostate Cancer Photodynamic Therapy (PDT) Study

Prostate cancer is the most common cancer in men, and the second leading cause of cancer deaths (25%) in Australia. One-in-Seven Australian men will be diagnosed with prostate cancer by the age of 85, with more than 3,300 men dying each year. There is a need for better treatment, combined with reliable assessments of treatment effectiveness.

This 3-month intervention study aims to assess the treatment effectiveness and safety of PDT for patients with biopsy proven prostate cancer using fluorescent photography imaging plus pre / post urinary proteomics (analysis of proteins in the urine) and Circulating Tumour Cell (CTC) specimen analyses.

For our research we are SEEKING 50-80-YEAR-OLD MALES who would like to participate in this study.

Patients who meet the following criteria can participate in the study:

  1. Men between 50-80 years diagnosed with biopsy proven primary prostate cancer
  2. Men diagnosed with local prostate cancer relapse after treatment
  3. Not planning other treatment in the next 3 months
  4. Not presenting with secondary metastatic prostate cancer

What’s involved?

  1. There will be 8 visits to NIIM (Melbourne) over 3 months.
  2. The first and the last visit will take about 30 min and will involve blood test, urine test, and questionnaires.
  3. There will be 12 treatment sessions on 6 days. Participants need to consider 3 x 2 full days for treatment.
  4. The morning (AM) PDT laser session of 25 minutes is followed by 4 hours break, leading to the 2nd afternoon (PM) PDT laser session lasting 25 minutes.
  5. A subgroup of participants will be allocated to a 3rd treatment session with the light bed, 4 hours after the 2nd PDT laser sessions on treatment days 2, 4 and 6 (Tue), respectively.

Light bed:


For more information

Participant Information and Consent Form

Expressions of interest, please complete the form below

Prostate Cancer Photodynamic Therapy (PDT) Enquiries

  • This field is for validation purposes and should be left unchanged.

or email directly to: / Subject heading: Prostate Cancer Treatment Study